Related Experiment Videos
Treatment modalities for hepatocellular carcinoma
1Laboratory of Molecular Endocrinology, Division of Cellular and Molecular Research, National Cancer Centre of Singapore, Singapore 169610. cmrhth@nccs.com.sg
Current Cancer Drug Targets
|April 7, 2005
Summary
Hepatocellular carcinoma (HCC) treatments lack proven survival benefits. New molecular therapies offer hope for this common cancer, with ongoing research focusing on improving systemic and targeted treatments.
Area of Science:
- Hepatology
- Oncology
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) is a prevalent global cancer with high mortality.
- Current treatments offer limited survival benefits for HCC patients.
- Surgical resection is only feasible for a small subset of patients.
Purpose of the Study:
- To review current treatment options for HCC.
- To explore emerging therapeutic advances in HCC management.
- To discuss the role of molecular targeted therapies in HCC.
Main Methods:
- Literature review of current HCC treatments.
- Analysis of recent advancements in molecular therapies for HCC.
- Discussion of ongoing and future clinical trials.
Main Results:
- No adjuvant or palliative HCC treatments have definitively prolonged survival.
- Local ablation, intra-arterial, and systemic treatments are primary modalities.
- Emerging therapies include antiangiogenesis, targeted therapy, and antisense gene targeting.
Conclusions:
- Understanding hepatocarcinogenesis drives new preventative and treatment strategies.
- Systemic and targeted molecular therapies show promise for HCC.
- Further research and clinical trials are crucial for optimizing HCC treatment.